Figure 2

Influence of Bisphosphonates intake on PFS and OS.

Kaplan-Meier curves were drawn in order to compare PFS and OS with regard to BP intake in four study groups. DTC-negative patients who had received ZOL seemed to have a worse PFS when compared to DTC-negative patients taking no BPs [p = 0.014; HR 3.268 (1.277–8.364)] as well as to DTC-positive patients who took clodronate [p = 0.025; HR 0.332 (0.126–0.873)]. No significant differences with regard to OS were found between the four groups analyzed. CTC-positive patients who had received clodronate, had a significantly shorter PFS than CTC-negative patients receiving no BPs [p = 0.040; HR 2.629 (1.049–6.591]. No differences in all four groups were shown for OS. Bivariable Cox Regression model-estimated survival curves. Black dotted line = DTC negative patients without BPs [n = 299], black solid line = DTC negative patients with BPs (zoledronic acid) [n = 15], orange dotted line = DTC positive patients without BPs [n = 43], orange solid line = DTC positive patients with BPs [n = 164], blue dotted line = CTC negative patients without BPs [n = 196], blue solid line = CTC negative patients with BPs [n = 94], red dotted line = CTC positive patients without BPs [n = 58], red solid line = CTC positive patients with BPs [n = 25].